The DTNA Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-HEP-1 human liver adenocarcinoma cell line, engineered for targeted disruption of the DTNA gene. This polyclonal pool provides a heterogeneous loss-of-function model, enabling robust functional studies without clonal selection, and is ideal for high-throughput screening and bulk biochemical assays.
The SK-HEP-1 host line is a human hepatic adenocarcinoma cell line that displays endothelial-like features, including expression of endothelial markers such as PECAM-1 and von Willebrand factor. This dual phenotype makes it a versatile model for investigating liver cancer biology in conjunction with vascular processes, particularly angiogenesis, tumor?Cendothelium interactions, and metastatic mechanisms. The endothelial characteristics of SK-HEP-1 offer a pertinent background for examining DTNA??s role in cytoskeletal organization and cell?Cmatrix adhesion.
The DTNA gene product, dystrobrevin alpha, is a core scaffolding protein of the dystrophin-associated protein complex (DAPC), which mechanically couples the intracellular actin cytoskeleton to the extracellular matrix through interactions with dystroglycans and the sarcoglycan subcomplex (??-, ??-, ??-, ??-sarcoglycan). Dystrobrevin alpha directly binds dystrophin, syntrophins (SNTA1, SNTB1), and dysbindin (DBND), facilitating the recruitment of signaling molecules such as neuronal nitric oxide synthase (nNOS) to the cell membrane, thereby regulating mechanotransduction and maintaining membrane stability. DTNA transcription is governed by myogenic regulatory factors (MyoD, MEF2) and modulated by Notch signaling, linking developmental pathways to DAPC assembly and function.
In the context of SK-HEP-1 endothelial-like liver cancer cells, DTNA deletion allows researchers to elucidate the contribution of dystrobrevin alpha to processes vital for tumor progression, including cell adhesion, migration, and invasion, which are intimately linked to metastasis and angiogenesis. Impairment of DAPC-mediated anchorage and nNOS signaling upon DTNA loss can disrupt cytoskeletal dynamics and focal adhesion turnover, providing a cellular system to investigate the interplay between dystrophin complex components and endothelial-like behavior, with implications for both hepatic malignancies and vascular disorders.
This polyclonal knockout population is amenable to a wide range of experimental applications. Researchers can profile DAPC components via western blotting for DTNA, dystrophin, and syntrophins; quantify DTNA transcript levels by RT-qPCR; and visualize dystrophin localization using immunofluorescence. Functional phenotyping may include migration and invasion assays, adhesion assays, and phospho-nNOS analysis. The model is particularly useful for drug screening campaigns targeting muscular dystrophy and cardiomyopathy, as well as for dissecting the mechanistic nuances of the dystrophin complex in cancer biology. For additional technical information, please contact Ascent Research.
